<DOC>
	<DOC>NCT00962871</DOC>
	<brief_summary>This open-label, randomized, parallel-arm study will assess the early immunologic response in treatment-na√Øve Asian male patients with chronic hepatitis B after initiation of treatment with Pegasys or tenofovir or Pegasys plus tenofovir. Patients will be randomized to one of 4 cohorts to receive either Pegasys (360mcg subcutaneously weekly) or tenofovir (300mg orally daily) or both or no treatment for 2 weeks. After 2 weeks on study treatment, patients may opt to receive standard of care treatment with Pegasys. Target sample size is &lt;50.</brief_summary>
	<brief_title>A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>male adults of Southeast and/or East Asian origin, 1855 years of age HBeAgpositive chronic hepatitis B detectable HBV DNA prior antiviral therapy for chronic hepatitis B evidence of bridging fibrosis, cirrhosis or decompensated liver disease positive test at screening for HAV (IgM), HCV, HDV or HIV history or evidence of medical condition associated with chronic liver disease antineoplastic or immunomodulatory treatment &lt;/=6 months prior to first dose of study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>